



RSP appoints Michael Gerstenberg as Chief Science Officer and Sune K-Holm Nielsen as Chief Commercial Officer

RSP strengthens our team by adding two industry veterans: scientific and technical expert Michael Gerstenberg, and digital health leader, Sune K-Holm Nielsen. Michael and Sune will add fuel to our efforts toward achieving U.S. market approval of our state-of-the-art technology.

During the past year, RSP ran a large clinical study with more than 160 patients and proved that the performance of its non-invasive device is ready for our pivotal study. The results are terrific, enabling the Company to attracting experienced forces from the industry and from the digital health sector.

Anders Weber, Chief Executive Officer at RSP, said: *“We are proud of the performance that we have seen in our recent clinical study, which is an important step forward for the future in diabetes prevention and management. We believe that the ability to measure glucose non-invasively will be a game-changer and to accelerate our efforts we succeeded hiring two experienced executive leaders to strengthen our management team. This will strengthen our position as the leading technology provider of non-invasive glucose measuring solutions both for diabetes management as well as for digital health applications.”*

RSP Systems has developed its Touch Glucose Monitoring technology through several iterations always guided by clinical studies and has now matured the device to a stage ready for the regulatory approval processes of FDA and for commercialization.

Sune has more than 10 years of experience in the digital health space. He joins RSP from Kry-Livi, where he held several leadership roles of huge impact to the company, including Director of Global Partnerships, Director of Psychology, and most recently Director of Global New Business. Sune has a strong track record in delivering digital health applications to the fast-growing market. Before his time at Kry-Livi, he was Managing Director of another digital health company, MeeDoc.

Sune K-Holm Nielsen, Chief Commercial Officer at RSP, said: *“I am amazed about the improvement in quality-of-life this technology will bring to millions of people of around the world – this is truly groundbreaking”.*

This latest addition to RSP’s management team follows a recent appointment of Michael Gerstenberg, PhD, as Chief Science Officer. Michael has more than 20 years of leadership experience from the medical device and pharmaceutical industry. He joined RSP from KLIFO, where he served as Project Director and led various medical device projects. Prior to this, he held several positions at Novo Nordisk, including Scientific Director, Corporate Vice President Partner and most recently Research Project Director.

Michael Gerstenberg, Chief Science Officer at RSP, said: *“RSP is on a really exiting path towards the holy grail of glucose monitoring - a non-invasive and portable device. The recent clinical results have demonstrated a remarkable performance of RSPs technology which can pave the way towards the market and further technological advance. I look much forward to be a part of this journey.”*

These appointments follow the company’s recent breakthrough results and the imminent closure of the company’s Series C round. The company is working to bring the world’s first truly non-invasive glucose



monitoring device targeting prevention and care of diabetes to the U.S market. In addition to this program, RSP aims to further miniaturize the technological pipeline of additional non-invasive touch glucose monitoring™ devices.

About RSP

RSP was founded in 2006 as a spin-out from the Biophotonics Group at the University of Southern Denmark (SDU). Today, the company employs more than 36 employees. RSP is developing the world's first non-invasive glucose monitor based on Raman spectroscopy - a mature technology - to which RSP has developed and patented various aspects. Conventional optical methods and artificial intelligence (AI) allows measurement of concentrations of various substances, including glucose, in the interstitial fluid - **completely non-invasively** - through the skin. We call this **touch glucose monitoring**.

RSP is transforming how we measure health! Our mission is to make glucose sensing so appealing that we can touch the lives of virtually everyone in the world.

For further information, please contact:

RSP Systems A/S

Anders Weber, CEO

Email: andersw@rspsystems.com